{
  "id": "SQ-LIP-000025",
  "question": "What specific genetic variants or inheritance patterns have been identified in lipedema?",
  "question_pt": "Quais variantes genéticas específicas ou padrões de herança foram identificados no lipedema?",
  "phrasings": [
    "Which particular gene mutations or hereditary patterns have been linked to lipedema?",
    "Is lipedema inherited, and what specific genetic variants are known to be involved?",
    "lipedema genetic variants inheritance pattern identified",
    "What genes and modes of inheritance have researchers found associated with lipedema?"
  ],
  "phrasings_pt": [
    "Quais mutações genéticas específicas ou padrões hereditários foram associados ao lipedema?",
    "O lipedema é herdado e quais variantes genéticas específicas já são conhecidas?",
    "lipedema variantes genéticas padrão de herança identificadas",
    "Que genes e formas de herança os pesquisadores encontraram relacionados ao lipedema?"
  ],
  "knowledge_state": "speculative",
  "tags": [
    "Genetics",
    "Etiology"
  ],
  "keywords": [
    "genetic variants",
    "inheritance pattern",
    "familial",
    "gene mutations"
  ],
  "current_answer": "Based on currently indexed evidence, no single gene or definitive Mendelian inheritance pattern has been confirmed for primary non-syndromic lipedema; the data consistently point to a polygenic/oligogenic complex trait with genetic heterogeneity. Familial clustering is well documented, with positive family history reported in roughly 15% to 89% of cases across studies (≈14.9% of probands with an affected first-degree relative in one series of 67 probands; up to 64–89% in reviews). The most frequently proposed mode is autosomal dominant inheritance with incomplete penetrance and sex limitation (female-preferential); X-linked dominant transmission was explicitly excluded by X-chromosome linkage analysis in the largest studied family (Li05; lod scores below -2), favoring autosomal dominant with sex limitation (moderate grade). Genome-wide association studies of UK Biobank women (24,450; European ancestry) identified 18 genome-wide significant loci (a polygenic signal), with VEGFA and GRB14-COBLL1 (plus ADAMTS9, LYPLAL1) replicating directionally in an independent clinically diagnosed cohort, and RSPO3 among the lead signals (moderate-grade cross-sectional GWAS); a smaller UK cohort GWAS (n=130) reported a suggestive (not genome-wide significant) signal at rs1409440 near LHFPL6 (OR_meta 2.01, P 4×10⁻⁶; low grade), and a 2022 GWAS in 130 carriers reported regions near CPE, ZNF25, and ZNF33A (estrogen biology). Family-based exome sequencing of 9 families (31 individuals, moderate grade) found candidate variants across 469 genes with no single shared gene, enriched in vasopressin receptor activity (AVPR1A, AVPR2), microfibril binding (FBN, ELN, LTBP), and Hedgehog/patched (PTCH1/2) pathways. A targeted 305-gene NGS panel in 162 patients (low-to-moderate grade) found heterozygous deleterious variants in 17 patients (~10.5%; 21 variants) across 12 genes involved in steroidogenesis, lipid homeostasis, and insulin signaling (PLIN1, LIPE, ALDH18A1, PPARG, GHR, INSR, RYR1, NPC1, POMC, NR0B2, GCKR, PPARA; PLIN1 c.722T>C is linked to familial partial lipodystrophy type 4). AKR1C-family genes have emerged as a recurrent candidate locus, supported by a familial AKR1C1 p.Leu213Gln (L213Q) missense variant segregating across three generations (reducing catalytic efficiency ~50% in progesterone metabolism), additional missense variants (L54V, L54F, N280K) predicted to disrupt substrate/cofactor (NADP+) binding, an AKR1C2 gain-of-function variant (Ser320PheTer2) and AKR1C2 overexpression in ~24% of mutation-negative patients, and regulatory SNPs (rs28571848 at a glucocorticoid-receptor site, rs34477787 at an RORα site); however, these derive from low-grade reviews, basic-science/computational work, and single families. Lower-grade or single-source findings also include a familial PIT1/POU1F1 mutation, altered expression of ZNF423, CAV1, CCND1, CYP19A1 (aromatase), COL6A3, and MMP14, and an IL-6 rs1800795 (-174G/C) G-allele association (OR=5.92) from a single small case-control study. Syndromic forms with overlapping fat phenotypes have defined mutations (e.g., POU1F1A c.196C>T p.Pro24Leu, NSD1/Sotos p.Cys2175Ser, 7q11.23/Williams-Beuren involving ELN/FZD9/MLXIPL, ABCC6/PXE, ALDH18A1/cutis laxa). Reviews emphasize no overlap with primary lymphedema or classic lipodystrophy genes, and that genetic studies overall remain underpowered.",
  "current_answer_pt": "Com base nas evidências atualmente indexadas, nenhum gene único ou padrão de herança mendeliana definitivo foi confirmado para o lipedema primário não sindrômico; os dados apontam consistentemente para um traço complexo poligênico/oligogênico com heterogeneidade genética. O agrupamento familiar está bem documentado, com história familiar positiva relatada em cerca de 15% a 89% dos casos entre estudos (≈14,9% dos probandos com parente de primeiro grau afetado em uma série de 67 probandos; até 64–89% em revisões). O modo mais frequentemente proposto é herança autossômica dominante com penetrância incompleta e limitação ao sexo (preferência feminina); a transmissão dominante ligada ao X foi explicitamente excluída por análise de ligação do cromossomo X na maior família estudada (Li05; escores lod abaixo de -2), favorecendo autossômica dominante com limitação ao sexo (grau moderado). Estudos de associação ampla do genoma (GWAS) em mulheres do UK Biobank (24.450; ascendência europeia) identificaram 18 loci significativos em escala genômica (sinal poligênico), com VEGFA e GRB14-COBLL1 (além de ADAMTS9, LYPLAL1) replicando direcionalmente em coorte independente diagnosticada clinicamente, e RSPO3 entre os sinais principais (GWAS transversal de grau moderado); um GWAS de coorte britânica menor (n=130) relatou sinal sugestivo (não significativo em escala genômica) em rs1409440 perto de LHFPL6 (OR_meta 2,01, P 4×10⁻⁶; grau baixo), e um GWAS de 2022 em 130 portadoras relatou regiões perto de CPE, ZNF25 e ZNF33A (biologia do estrogênio). O sequenciamento de exoma baseado em famílias de 9 famílias (31 indivíduos, grau moderado) encontrou variantes candidatas em 469 genes sem nenhum gene compartilhado, enriquecidas em atividade do receptor de vasopressina (AVPR1A, AVPR2), ligação a microfibrilas (FBN, ELN, LTBP) e vias Hedgehog/patched (PTCH1/2). Um painel NGS direcionado de 305 genes em 162 pacientes (grau baixo a moderado) encontrou variantes deletérias heterozigotas em 17 pacientes (~10,5%; 21 variantes) em 12 genes envolvidos em esteroidogênese, homeostase lipídica e sinalização de insulina (PLIN1, LIPE, ALDH18A1, PPARG, GHR, INSR, RYR1, NPC1, POMC, NR0B2, GCKR, PPARA; PLIN1 c.722T>C ligada à lipodistrofia parcial familiar tipo 4). Os genes da família AKR1C surgiram como locus candidato recorrente, apoiados por uma variante missense familiar AKR1C1 p.Leu213Gln (L213Q) segregando por três gerações (reduzindo a eficiência catalítica em ~50% no metabolismo da progesterona), variantes missense adicionais (L54V, L54F, N280K) previstas para perturbar a ligação ao substrato/cofator (NADP+), uma variante de ganho de função AKR1C2 (Ser320PheTer2) e superexpressão de AKR1C2 em ~24% dos pacientes sem mutação, e SNPs regulatórios (rs28571848 em sítio do receptor de glicocorticoide, rs34477787 em sítio RORα); contudo, esses derivam de revisões de baixo grau, trabalho básico/computacional e famílias isoladas. Achados de grau inferior ou de fonte única também incluem uma mutação familiar PIT1/POU1F1, expressão alterada de ZNF423, CAV1, CCND1, CYP19A1 (aromatase), COL6A3 e MMP14, e uma associação do alelo G de IL-6 rs1800795 (-174G/C) (OR=5,92) de um único pequeno estudo caso-controle. Formas sindrômicas com fenótipos de gordura sobrepostos têm mutações definidas (ex.: POU1F1A c.196C>T p.Pro24Leu, NSD1/Sotos p.Cys2175Ser, 7q11.23/Williams-Beuren envolvendo ELN/FZD9/MLXIPL, ABCC6/PXE, ALDH18A1/cutis laxa). As revisões enfatizam que não há sobreposição com linfedema primário ou genes clássicos de lipodistrofia, e que os estudos genéticos permanecem subdimensionados.",
  "major_uncertainty": "No causal gene or definitive inheritance pattern is established for primary non-syndromic lipedema. The strongest available evidence is moderate at best (a UK Biobank GWAS using an inferred rather than clinically diagnosed phenotype, and family-based exome sequencing in small samples); nearly all variant-level findings (AKR1C1/AKR1C2, IL-6, candidate-gene panel hits) come from single families, small case series, computational predictions, or narrative reviews and lack independent replication in adequately powered, clinically diagnosed cohorts. Whether the proposed autosomal-dominant/sex-limited model or a polygenic/oligogenic model best describes inheritance remains unresolved, and the relative contribution of any individual candidate gene is unquantified.",
  "version": "1.3",
  "created": "2026-05-31",
  "updated": "2026-05-31",
  "evidence_direction": {
    "supporting": 10,
    "contradicting": 0,
    "other": 4
  },
  "knowledge_freshness": {
    "pct": 82,
    "sources": 17,
    "newest": 2026,
    "oldest": 2010,
    "label": "current evidence base"
  },
  "claims": [
    {
      "id": "SCR-LIP-000214",
      "role": "supporting",
      "statement": "In a case-control study using TaqMan genotyping, carriers of the IL-6 rs1800795 (-174G/C) G allele (CG+GG) had a 5.92-fold higher risk of lipedema versus non-carriers (CC) (OR=5.92, 95%CI 1.983–17.711, p<0.001), with samples in Hardy-Weinberg equilibrium."
    },
    {
      "id": "SCR-LIP-000215",
      "role": "refines",
      "statement": "Family-based exome sequencing of 31 individuals from 9 lipedema families identified candidate variants in 469 genes with no single gene shared across all families, supporting genetic heterogeneity rather than a Mendelian single-gene cause, with gene ontology enrichment in vasopressin receptor activity (AVPR1A, AVPR2), microfibril binding (FBN, ELN, LTBP), and patched binding (PTCH1/2, Hedgehog pathway)."
    },
    {
      "id": "SCR-LIP-000216",
      "role": "supporting",
      "statement": "A 305-gene NGS panel applied to 162 lipedema patients identified 21 heterozygous deleterious variants in 17 patients (10.5%) across 12 genes (PLIN1, LIPE, PPARG, POMC, NR0B2, GCKR, NPC1, ALDH18A1, GHR, INSR, RYR1, PPARA), most involved in steroidogenesis, lipid homeostasis, and insulin signaling, including PLIN1 c.722T>C linked to familial partial lipodystrophy type 4."
    },
    {
      "id": "SCR-LIP-000217",
      "role": "supporting",
      "statement": "This systematic review reports specific genetic findings in lipedema including an AKR1C1 missense variant (Michelini 2020) associated with reduced progesterone clearance and increased adipogenesis, a familial Pit1 mutation causing GH and testosterone deficiency (Bano 2010), and upregulation of ZNF423 and CAV1 dysfunction, supporting a possible genetic susceptibility component."
    },
    {
      "id": "SCR-LIP-000218",
      "role": "context",
      "statement": "A systematic review of lipedema pathology reported that, despite growing histological and molecular research, the aetiology remains largely uncertain; it noted differential gene expression in lipedema adipose-derived stem cells (3429 genes, including cell-cycle genes Bub1, CDC20, BIRC5 per Ishaq) but did not identify specific inherited variants or defined inheritance patterns."
    },
    {
      "id": "SCR-LIP-000233",
      "role": "supporting",
      "statement": "In a series of 67 probands, 14.9% had a first-degree relative with confirmed lipedema and X-chromosome linkage analysis in the largest family (Li05) returned lod scores below -2, excluding X-linked dominant inheritance and favoring autosomal dominant inheritance with sex limitation."
    },
    {
      "id": "SCR-LIP-000234",
      "role": "context",
      "statement": "This narrative review describes lipedema as having a hereditary component with familial inheritance and notes shared and distinct genetic markers between lipedema and lymphedema, but the abstract is truncated before specifying particular genetic variants or inheritance patterns."
    },
    {
      "id": "SCR-LIP-000235",
      "role": "supporting",
      "statement": "This review reports lipedema as polygenic with familial history in 30-89% of cases, citing a 2022 GWAS (130 carriers) identifying 6 regions (CPE, ZNF25, ZNF33A linked to estrogen biology), a UK Biobank study (24,450 women) finding 18 loci replicating VEGFA and GRB14-COBLL1, a partial loss-of-function missense variant in AKR1C1 in a non-syndromic lipedema family, and a multigene panel of 305 loci finding 17 probable deleterious lesions in 21/162 participants, with no single causal gene and no overlap with primary lymphedema or lipodystrophies."
    },
    {
      "id": "SCR-LIP-000236",
      "role": "supporting",
      "statement": "A GWAS of a UK lipedema cohort (n=130) identified a suggestive association (not genome-wide significant) at SNP rs1409440 (OR_meta 2.01; P_meta 4×10⁻⁶) located upstream of LHFPL6, a gene involved in lipoma formation, with additional support from an independent 100,000 Genomes replication cohort."
    },
    {
      "id": "SCR-LIP-000237",
      "role": "context",
      "statement": "This review cites whole-exome sequencing (Michelini et al., 2020) associating lipedema with variants in sex-hormone-related genes involved in subcutaneous fat deposition, and proposes that dysregulated estrogen receptor (ERα/ERβ) signaling and local adipose estrogen production contribute to lipedema pathophysiology."
    },
    {
      "id": "SCR-LIP-000238",
      "role": "supporting",
      "statement": "This systematic review reports that lipedema most likely follows autosomal dominant inheritance with incomplete penetrance and sex limitation (positive family history in up to 64% of women), identifies no confirmed gene for primary non-syndromic lipedema, and catalogs syndromic associations (POU1F1A c.196C>T p.Pro24Leu; NSD1 p.Cys2175Ser/Sotos; 7q11.23 deletion/Williams-Beuren with ELN, FZD9, MLXIPL; ABCC6/PXE; ALDH18A1/cutis laxa III) plus 17 GWAS/animal-model candidate genes (e.g., LYPLAL1, TBX15, HOXC13, RSPO3, VEGFA, PROX1, VEGFR3, PRDM16)."
    },
    {
      "id": "SCR-LIP-000239",
      "role": "supporting",
      "statement": "This narrative review reports that lipedema follows a female-preferential autosomal dominant inheritance pattern and is associated with altered expression of specific genes including CCND1, ZNF423, CYP19A1 (aromatase), COL6A3, and MMP14, while noting that genetic studies remain underpowered."
    },
    {
      "id": "SCR-LIP-000240",
      "role": "supporting",
      "statement": "This review identifies specific lipedema-associated variants in AKR1C genes, including the familial AKR1C1 p.Leu213Gln (L213Q) mutation segregating across three generations and reducing catalytic efficiency ~50%, the gain-of-function AKR1C2 Ser320PheTer2 mutation, AKR1C2 overexpression in 24% (5/21) of patients without coding mutations, and regulatory SNPs rs28571848 (glucocorticoid receptor site) and rs34477787 (RORα site) that increase AKR1C2/AKR1C3 expression and truncal fat mass independent of BMI."
    },
    {
      "id": "SCR-LIP-000241",
      "role": "supporting",
      "statement": "Targeted NGS and molecular dynamics simulations identified three missense AKR1C1 variants (L54V, L54F, N280K) in lipedema patients that disrupt substrate or cofactor (NADP+) binding, and screening of gnomAD identified 8 rare AKR1C1 polymorphisms as potentially pathogenic, extending AKR1C1 as a candidate gene for autosomal dominant non-syndromic lipedema."
    }
  ],
  "references": [
    "DOI:10.26355/eurrev_202003_20690",
    "DOI:10.1089/lrb.2023.0065",
    "DOI:10.3390/jpm12020268",
    "DOI:10.1111/obr.13953",
    "DOI:10.1007/s00404-026-08318-1",
    "DOI:10.3390/jpm13010098",
    "DOI:10.1055/a-2183-7414",
    "DOI:10.1002/ajmg.a.33313",
    "DOI:10.3390/ijms23126621",
    "DOI:10.1038/s44324-025-00093-y",
    "DOI:10.1038/s41431-022-01231-6",
    "DOI:10.1371/journal.pone.0274867",
    "DOI:10.3390/ijms222111720",
    "DOI:10.26355/eurrev_201907_18292",
    "DOI:10.3390/biomedicines10123081",
    "DOI:10.4081/vl.2026.15495",
    "DOI:10.26355/eurrev_202312_34698"
  ],
  "cite": "Scientific Claim Registry. What specific genetic variants or inheritance patterns have been identified in lipedema?. SQ-LIP-000025 v1.3; 2026-05-31. https://scientificclaims.org/q/SQ-LIP-000025/v1.3.html",
  "versions": [
    {
      "version": "1.3",
      "date": "2026-05-31",
      "url": "https://scientificclaims.org/q/SQ-LIP-000025/v1.3.html"
    },
    {
      "version": "1.2",
      "date": "2026-05-31",
      "url": "https://scientificclaims.org/q/SQ-LIP-000025/v1.2.html"
    },
    {
      "version": "1.1",
      "date": "2026-05-31",
      "url": "https://scientificclaims.org/q/SQ-LIP-000025/v1.1.html"
    },
    {
      "version": "1.0",
      "date": "2026-05-31",
      "url": "https://scientificclaims.org/q/SQ-LIP-000025/v1.0.html"
    }
  ],
  "url": "https://scientificclaims.org/q/SQ-LIP-000025.html",
  "url_pt": "https://scientificclaims.org/pt/q/SQ-LIP-000025.html",
  "version_url": "https://scientificclaims.org/q/SQ-LIP-000025/v1.3.html",
  "license": "CC-BY-4.0",
  "disclaimer": "Evidence-bounded summary; not medical advice."
}